OSCR
Oscar Health, Inc.
OSCR has the edge over V overall, supported by stronger fundamentals and stronger valuation.
V
Visa Inc.
V has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
V Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
V's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like V.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over V in the historical PE scenario, which offers more potential upside but is not a forecast.
V PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $420 | — |
| Cheap | 30x | $371 | -12% |
| Fair | 33x | $402 | -4.4% |
| Current | 34x | $420 | — |
| Expensive | 38x | $474 | +13% |
Historical ranges are pointers, not guarantees.
V's PE is in its fair range at 34x. If earnings grow as analysts expect, today's price would be 28x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
V Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for V, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
V Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.01 | +22% |
| Q3 2026 | $12.32 | +21% |
| Q2 2026 | $11.76 | +15% |
| Q1 2026 | $11.48 | +15% |
| Q4 2025 | $10.66 | +7.5% |
| Q3 2025 | $10.21 | +4.9% |
| Q2 2025 | $10.24 | +9.5% |
| Q1 2025 | $9.95 | +11% |
| Q4 2024 | $9.92 | +14% |
V has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over V on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
V Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.1B | +13% |
| Q2 2026 | $11.6B | +14% |
| Q1 2026 | $11.2B | +17% |
| Q4 2025 | $10.9B | +15% |
| Q3 2025 | $10.7B | +12% |
| Q2 2025 | $10.2B | +14% |
| Q1 2025 | $9.6B | +9.3% |
| Q4 2024 | $9.5B | +10% |
V's revenue has grown year over year for 22 quarters in a row: $12.1B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 60% | +2.5 points |
| Q2 2026 | 59% | -1.6 points |
| Q1 2026 | 64% | +7.8 points |
| Q4 2025 | 62% | -3.8 points |
| Q3 2025 | 57% | -8.7 points |
| Q2 2025 | 61% | -6 points |
| Q1 2025 | 57% | -4.4 points |
| Q4 2024 | 66% | -3.4 points |
V has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over V on cash flow, with more consistent year-over-year improvement.
V Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9B | +18% |
| Q2 2026 | $6.1B | -2.7% |
| Q1 2026 | $2.6B | -40% |
| Q4 2025 | $6.4B | +27% |
| Q3 2025 | $5.8B | -8% |
| Q2 2025 | $6.3B | +33% |
| Q1 2025 | $4.4B | +2.6% |
| Q4 2024 | $5.1B | +51% |
V's free cash flow was $22.1B over the past year, up 2.2% from the year before. Free cash flow isn't a meaningful measure for financial services companies like V.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
V Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7% | -136M shares |
| 1 year | -7.6% | -148M shares |
| 3 years | -13% | -268M shares |
| 5 years | -17% | -378M shares |
| Available history | -20% | -443M shares |
V has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4B |
| Q2 2026 | $4.8B |
| Q1 2026 | $7.9B |
| Q4 2025 | $3.7B |
| Q3 2025 | $4.9B |
| Q2 2025 | $4.8B |
| Q1 2025 | $4.6B |
| Q4 2024 | $4B |
V spent $20.5B buying back its own shares over the past year, up 12% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over V on leverage, with a lower net debt burden relative to earnings.
V Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.3x | Very low |
V's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like V.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
V Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 82.0 | Overbought |
V's weekly RSI is 74 (overbought) and its Stochastic is 82 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over V on valuation relative to its sector.
V PE vs Financial Services Sector
| Metric | V | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 13x | 162% above |
| PE % | 62 | 63 | 1 pt below |
V is trading at 34x earnings, a 162% premium to the Financial Services sector's median of 13x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
V Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $397.6 | 5.7% above |
| 20 week MA | $378.3 | 11% above |
| 50 week MA | $346.0 | 21% above |
| 100 week MA | $343.7 | 22% above |
| 200 week MA | $300.6 | 40% above |
V is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over V on returns for 2026, with the stronger performance.
V Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $189.4 | $208.7 | +10% |
| 2021 | $208.7 | $216.6 | +3.8% |
| 2022 | $216.6 | $205.8 | -5% |
| 2023 | $205.8 | $260.4 | +26% |
| 2024 | $260.4 | $318.7 | +22% |
| 2025 | $318.7 | $355.0 | +11% |
| 2026 YTD | $355.0 | $420.3 | +18% |
V has finished higher in five of the last six years. It's up 18% so far in 2026.